Could this be the secret to Pfizer's rebound strategy?

It could prove to be a case of better later than never for the healthcare giant.

Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.

Pfizer Inc. said an experimental drug failed to improve survival in patients with an advanced form of lung cancer that couldn ...

Everyone is still arguing about Novo Nordisk (NYSE:NVO | NVO Price Prediction), the Danish obesity juggernaut whose GLP-1 ...

The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...

Passive income is the closest thing investors have to financial gravity. It pulls in money whether you are at your desk, on a ...

By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary ...

U.S. District Judge M. Casey Rodgers, in the Northern District of Florida, postponed her expert ruling this month due to a ...

Shares of Pfizer Inc. PFE slipped 1.19% to $24.08 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.79% to 7,499.36 and the ...

Pfizer said on Thursday that finance chief Dave Denton will leave ⁠on August 15 to return to the consumer goods industry.